Adding lanreotide to everolimus significantly prolonged progression-free survival compared with everolimus alone in patients with gastroenteropancreatic neuroendocrine tumors, a phase 3 trial found.

Exelixis reported $515.2M in net product revenues in Q4'24, a 20% increase over net product revenues for Q4'23. See why I ...

There are 2 key groups of neuroendocrine cancer: neuroendocrine tumours (NETs ... They can also rarely start in other organs of the body such as the bowel, lungs and liver. It’s a worrying time for ...

“These medicines will give people more treatment options and help them to live well for longer,” says Pharmac’s Director Equity and Engagement, Dr Nicola Ngawati. “We expect about 180 people will ...

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic ...

The combination of chemotherapy and radioembolization appeared safe and effective in patients with well-differentiated, liver-dominant, grade 3 NETs.

Because of this you usually won’t be able to have TAE if you have moderate or severe liver damage (cirrhosis). Contact the hospital if you have an increase in pain and get a temperature when you are ...

Some people use Zollinger-Ellison syndrome and gastrinoma interchangeably. Learn the similarities and differences between the ...

Dr. Jonathan R. Strosberg, discussed results of the CABINET trial evaluating Cabometyx versus placebo in advanced ...

Tragically, it claims the lives of 9,558 people annually, with over 70% succumbing within a year of being diagnosed. Just one ...

Operator Good day, ladies and gentlemen, and welcome to the Exelixis fourth quarter and fiscal year 2024 financial results ...

Tragically, it claims the lives of 9,558 people annually, with over 70% succumbing within a year of being diagnosed. Just one ...